@article{MTMT:34476377,
	title = {Láthatatlan (EKG) nyomon: kardiogén, neurogén vagy iatrogén syncope?},
	url = {https://m2.mtmt.hu/api/publication/34476377},
	author = {Gausz, Flóra Diána and Pap, Róbert and Benák, Attila and Miklós, Márton and Horváth, Zoltán and Irsai, Ákos and Bencsik, Gábor and Makai, Attila and Sághy, László and Vámos, Máté},
	doi = {10.26430/CHUNGARICA.2023.53.6.614},
	journal-iso = {CARDIOL HUNG},
	journal = {CARDIOLOGIA HUNGARICA},
	volume = {53},
	unique-id = {34476377},
	issn = {0133-5596},
	year = {2023},
	eissn = {1588-0230},
	pages = {614-618},
	orcid-numbers = {Pap, Róbert/0000-0002-7009-5063}
}

@article{MTMT:32804732,
	title = {Localization of macroscopically undetectable intramedullary hematoma by intraoperative epidural motor evoked potential},
	url = {https://m2.mtmt.hu/api/publication/32804732},
	author = {Horváth, Zoltán and Lukács, Melinda and Szivos, László and Barzó, Pál},
	doi = {10.1016/j.cnp.2022.04.001},
	journal-iso = {CLIN NEUROPHYSIOL PRACT},
	journal = {CLINICAL NEUROPHYSIOLOGY PRACTICE},
	volume = {7},
	unique-id = {32804732},
	issn = {2467-981X},
	year = {2022},
	pages = {129-134},
	orcid-numbers = {Szivos, László/0000-0001-8746-3726; Barzó, Pál/0000-0001-8717-748X}
}

@article{MTMT:31806072,
	title = {Az epilepsziás betegek ellátásának változása a COVID–19-járvány első veszélyhelyzeti periódusában [Changes in epilepsy care during the first medical emergency period of COVID-19 pandemic in Hungary]. Kérdőíves felmérés [A questionnaire survey]},
	url = {https://m2.mtmt.hu/api/publication/31806072},
	author = {Fabó, Dániel and Horváth, Zoltán and Klivényi, Péter and Kamondi, Anita},
	doi = {10.1556/650.2020.32003},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {161},
	unique-id = {31806072},
	issn = {0030-6002},
	year = {2020},
	eissn = {1788-6120},
	pages = {1939-1943},
	orcid-numbers = {Fabó, Dániel/0000-0001-5141-5351; Klivényi, Péter/0000-0002-5389-3266; Kamondi, Anita/0000-0001-9860-730X}
}

@CONFERENCE{MTMT:3379632,
	title = {„Aliter in theoria, aliter in praxi” esetismertetés},
	url = {https://m2.mtmt.hu/api/publication/3379632},
	author = {Kondász, Antal Gábor and Menczel, E and Fodor, Domonka Gabriella and Horváth, Zoltán and Terhes, Gabriella and Hajdú, Edit},
	booktitle = {A Magyar Infektológiai és Klinikai Mikrobiológiai Társaság 44. kongresszusa},
	unique-id = {3379632},
	year = {2016},
	pages = {36},
	orcid-numbers = {Terhes, Gabriella/0000-0002-7301-9672}
}

@article{MTMT:3137890,
	title = {Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies},
	url = {https://m2.mtmt.hu/api/publication/3137890},
	author = {Dézsi, Livia and Horváth, Zoltán and Vécsei, László},
	doi = {10.1080/17425255.2016.1214715},
	journal-iso = {EXPERT OPIN DRUG MET},
	journal = {EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY},
	volume = {12},
	unique-id = {3137890},
	issn = {1742-5255},
	abstract = {Introduction: Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune and systemic inflammatory diseases with both licensed and off-label indications. The mechanism of action is complex and not fully understood, involving the neutralization of pathological antibodies, Fc receptor blockade, complement inhibition, immunoregulation of dendritic cells, B cells and T cells and the modulation of apoptosis. Areas covered: First, this review describes the pharmacological properties of IVIg, including the composition, mechanism of action, and adverse events. The second part gives an overview of some of the immune-mediated polyneuropathies, with special focus on the pathomechanism and clinical trials assessing the efficacy of IVIg. A literature search on PubMed was performed using the terms IVIg, IVIg preparations, side effects, mechanism of action, clinical trials, GBS, CIDP. Expert opinion: Challenges associated with IVIg therapy and the treatment possibilities for immune-mediated polyneuropathies are discussed. The availability of IVIg is limited, the expenses are high, and, in several diseases, a chronic therapy is necessary to maintain the immunomodulatory effect. The better understanding of the mechanism of action of IVIg could open the possibility of the development of disease-specific, targeted immune therapies. © 2016 Informa UK Limited, trading as Taylor & Francis Group.},
	keywords = {IVIG; CIDP; Sialylation; FC RECEPTORS; IgG molecule; GBS; anti-idiotype antibodies; anti-ganglioside antibodies},
	year = {2016},
	eissn = {1744-7607},
	pages = {1343-1358},
	orcid-numbers = {Vécsei, László/0000-0001-8037-3672}
}

@article{MTMT:2926768,
	title = {Diagnostic yield of five minutes compared to three minutes hyperventilation during electroencephalography},
	url = {https://m2.mtmt.hu/api/publication/2926768},
	author = {Craciun, Laura and Varga, Edina Tímea and Mindruta, I and Meritam, P and Horváth, Zoltán and Terney, D and Gardella, E and Alving, Jø and Vécsei, László and Beniczky, Sándor},
	doi = {10.1016/j.seizure.2015.06.003},
	journal-iso = {SEIZURE-EUR J EPILEP},
	journal = {SEIZURE-EUROPEAN JOURNAL OF EPILEPSY},
	volume = {30},
	unique-id = {2926768},
	issn = {1059-1311},
	abstract = {Purpose To investigate whether hyperventilation (HV) for 5 min increases the diagnostic yield of electroencephalography (EEG) compared to 3 min HV. Methods data were evaluated from 1084 consecutive patients, from three European centres, referred to EEG on suspicion of epilepsy. Seizures and interictal EEG abnormalities precipitated during the first 3 min and during the last 2 min of the HV period (totally 5 min) were determined. Results Eight hundred seventy-seven patients (81%) completed 5 min HV. Seizures were precipitated during the first 3 min of HV in 21 patients, and during the last 2 min in four more patients. Interictal EEG abnormalities were precipitated in the first 3 min of HV in 16 patients, and during the last 2 min in 7 more patients. Psychogenic nonepileptic seizures occurred in eight patients during the first 3 min of HV and in two more patients during the last 2 min. No adverse events occurred during the last 2 min of HV, but eight patients (1%) stopped HV during the last 2 min because they were not able to hyperventilate further. Conclusion 16% of seizures and 30% of interictal EEG abnormalities triggered by HV occurred during the last 2 min of HV, suggesting the clinical usefulness of prolonged hyperventilation for 5 min. The vast majority of patients (99%) who are able to hyperventilate for 3 min can complete 5 min HV, without additional adverse events. © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.},
	keywords = {EEG; DURATION; hyperventilation; Diagnostic yield; PROVOCATION},
	year = {2015},
	eissn = {1532-2688},
	pages = {90-92},
	orcid-numbers = {Varga, Edina Tímea/0000-0002-9365-3689; Vécsei, László/0000-0001-8037-3672}
}

@article{MTMT:2825051,
	title = {Old and new neuroendocrine molecules. somatostatin, cysteamine, pantethine and kynurenine},
	url = {https://m2.mtmt.hu/api/publication/2825051},
	author = {Vécsei, László and Horváth, Zoltán and Tuka, Bernadett},
	journal-iso = {IDEGGYOGY SZEMLE},
	journal = {IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE},
	volume = {67},
	unique-id = {2825051},
	issn = {0019-1442},
	abstract = {The aim of this review is to commemorate Hans Selye, endocrinologist, the most famous researchers of stress and to briefly summarize the major features of somatostatin (SST), cysteamine (CysA) and patethine (PAN) in neuroen-docrinological aspect, which are closely related to his scientific work. In addition, some metabolites of kynurenine pathway (KP) were also mentioned in this paper, as new, possible target molecules in neuroendocrinology. R. Guillemin and A. V. Schally were the main pioneers of the discovery of SST in the 1970's. SST primarily is known as an inhibitor of growth hormone secretion and additionally reduces the gastric acid and pepsin release and also the gastroduodenal mucosal blood flow. These effects are very important in the pathophysiology of peptic ulcer bleeding, which is related to the CysA-evoked perforating duodenal ulcer experimental stress model in rats developed by Se lye and Szabo. CysA is a naturally occurring duodenal ulcerogen, which depletes SST in the gastric mucosa and certain brain regions. Furthermore, in addition to depleting SST, CysA also causes adrenocortical necrosis, suggesting an interaction between the central/peripheral nervous system and the neuroendocrine system. The antioxidant PAN, formulated besides the CysA, has similar effects: it attenuates the levels of SST and proladin in the cerebral cortex and hypothalamus through the accumulation of CysA within cells throughout the body. As new perspectives the KP may be involved in the modulation of neuroendrocrine processes: different agonists and antagonists of glutamate receptors regulate the hypothalamic-pituitary-adrenal axis and kynurenic acid augments the anxiolytic stress responses in neonatal chicks. The pro-inflammatory cytokine-induced and the toxic heavy oil contaminations-evoked alterations in the KP indirectly contribute to the development of neuroendocrine disorders. In summary, there have been highly important developments in neuroendocrinology since the early findings of Se lye. Although there are as yet relatively few data about the potential role of kynurenines in neuroendocrinology, the results already achieved are extremely noteworthy and immensely promising.},
	keywords = {GROWTH-HORMONE; CYSTEAMINE; SOMATOSTATIN; NEUROPEPTIDE-Y; MULTIPLE-SCLEROSIS; KYNURENINE; OPEN-FIELD BEHAVIOR; pantethine; PATHWAY METABOLISM; EXCITOTOXIN LESIONS; BRAIN CATECHOLAMINES; IMMUNOREACTIVE SOMATOSTATIN; QUINOLINIC ACID LESIONS; INHIBITING HORMONE SOMATOSTATIN},
	year = {2014},
	eissn = {2498-6208},
	pages = {107-112},
	orcid-numbers = {Vécsei, László/0000-0001-8037-3672; Tuka, Bernadett/0000-0002-1410-4666}
}

@article{MTMT:2776031,
	title = {Terhesség neuromyelitis opticában.},
	url = {https://m2.mtmt.hu/api/publication/2776031},
	author = {Zádori, Dénes and Horváth, Zoltán and Rajda, Cecília and Rokolya, Sz and Obál, Izabella and Szőnyegi, FL and Török, KT and Engelhardt, József István and Singh, M and Tóth, A and Novák, T and Pál, A and Vécsei, László and Klivényi, Péter},
	journal-iso = {IDEGGYOGY SZEMLE},
	journal = {IDEGGYOGYASZATI SZEMLE / CLINICAL NEUROSCIENCE},
	volume = {67},
	unique-id = {2776031},
	issn = {0019-1442},
	year = {2014},
	eissn = {2498-6208},
	pages = {13},
	orcid-numbers = {Zádori, Dénes/0000-0003-0749-7980; Rajda, Cecília/0000-0002-0252-4778; Engelhardt, József István/0000-0002-9880-1441; Vécsei, László/0000-0001-8037-3672; Klivényi, Péter/0000-0002-5389-3266}
}

@article{MTMT:1926307,
	title = {Treatment With Pantethine},
	url = {https://m2.mtmt.hu/api/publication/1926307},
	author = {Horváth, Zoltán and Vécsei, László},
	doi = {10.1177/1533210110392944},
	journal-iso = {J EVIDENCE-BASED COMPL ALTERN MED},
	journal = {JOURNAL OF EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE},
	volume = {16},
	unique-id = {1926307},
	issn = {2156-5872},
	abstract = {The current increase in cardiovascular and cerebrovascular morbidity is a growing burden for society. Consideration must therefore be given to compounds capable of slowing down these pathological processes without significant adverse effects. The natural vitamins pantetheine/pantothenic acid are major precursors of coenzyme A and acyl carrier protein, which are essential for fatty acid oxidation and participate in the metabolism of cholesterol and carbohydrates and in at least 70 other enzymatic processes. Following a number of theoretical considerations and clinical observations, various clinical studies have revealed that they possess significant beneficial effects. In particular, they demonstrate useful moderating effects on vascular pathological processes, lowering lipid levels, and inhibiting platelet functions and lipid peroxidation. Although they are natural, well-tolerated therapeutic agents, few controlled clinical trials have been conducted. The available data suggest the need for larger clinical trials and possible use of pantetheine/pantothenic acid as adjuvant therapy.},
	year = {2011},
	pages = {21-28},
	orcid-numbers = {Vécsei, László/0000-0001-8037-3672}
}

@article{MTMT:1527298,
	title = {Protein kinase inhibitor as a potential candidate for epilepsy treatment},
	url = {https://m2.mtmt.hu/api/publication/1527298},
	author = {Gajda, Z and Török, Rita and Horváth, Zoltán and Szántai-Kis, Csaba and Őrfi, László and Kéri, György and Szente, Magdolna},
	doi = {10.1111/j.1528-1167.2011.02979.x},
	journal-iso = {EPILEPSIA},
	journal = {EPILEPSIA},
	volume = {52},
	unique-id = {1527298},
	issn = {0013-9580},
	abstract = {P>Purpose: Effects of the "VID-82925" kinase inhibitor molecule were investigated both during the developing phase as well as during the stable phase of the focus with spontaneous recurrent seizures using the 4-AP-induced in vivo epilepsy model in anesthetized rats. Methods: In electrophysiologic experiments, VID-82925 (0.85 mg/kg) was injected intravenously either before the induction (pretreatment) or after the development of the stable focus (treatment). Reference drugs carbamazepine (4.8 mg/kg) and levetiracetam (50 mg/kg) were employed using the same experimental paradigm. The antiepileptic effect of VID-82925 was also compared to those of the broad-spectrum gap junction channel blocker carbenoxolone (10 mm). Key Findings: Pretreatment with VID-82925 revealed an antiepileptogenic effect as it suppressed significantly the manifestation of the epileptiform activity not only during the developing phase, but also for a considerable long period during the stable phase of the focus. The current data do not allow us to differentiate an antiictal treatment effect from an antiepileptogenic effect of the compound during the stable phase of the focus. Treatment with VID-82925 was also effective against ictogenesis during the stable phase of the focus. Pretreatment with levetiracetam failed to exert any antiepileptogenic effect. The antiepileptic effects of VID-82925 and of the reference drugs on the epileptiform activity of the stable focus were comparable in intensity; however, the effect of VID-82925 was 2-3 times longer. The effects of VID-82925 and of carbenoxolone overlapped one another to some extent, suggesting that VID-82925 may exert its effects at least partially through blocking of gap junctional communication. Significance: Our results indicate that inhibition of protein kinases may also provide an effective strategy for the development of a drug that is not only antiepileptic but also depresses the course of epileptogenesis.},
	keywords = {MODEL; IN-VITRO; SEIZURES; TEMPORAL-LOBE EPILEPSY; 4-AMINOPYRIDINE; ANTIEPILEPTIC DRUGS; In vivo; Kinase inhibitor; antiepileptic; levetiracetam; EPILEPTIFORM ACTIVITY; CONNEXIN PHOSPHORYLATION; GAP-JUNCTIONS; Antiepileptogenic},
	year = {2011},
	eissn = {1528-1167},
	pages = {579-588},
	orcid-numbers = {Őrfi, László/0000-0001-6149-2385}
}